Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 278 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Why do non-smokers face delays in getting a lung cancer diagnosis? November 25, 2022 Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... February 25, 2021 Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes... November 2, 2022 Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in... March 17, 2026 Load more HOT NEWS New obesity strategy is a ‘landmark day for the nation’s health’... FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... Coping With Advanced Melanoma and a Second Cancer Diagnosis: A Survivor’s...
